Cancer Home > Panitumumab Dosage

Your weight and whether you develop side effects are among the considerations your healthcare provider will take into account when determining your panitumumab dosage. The initial amount is normally 6 mg per kilogram of body weight, given intravenously (by IV) by your healthcare provider every 14 days. If you develop serious skin reactions, the drug may be stopped temporarily.

An Introduction to Your Dosage of Panitumumab

The dose of panitumumab (Vectibix®) your healthcare provider recommends will vary, depending on:
  • Your weight
  • Side effects you experience.
As is always the case, do not adjust your dosage unless your healthcare provider specifically tells you to do so.

Panitumumab Dosing Guidelines

The standard dosage of panitumumab for the treatment of advanced colorectal cancer is 6 mg per kg body weight (about 2.7 mg per lb) every 14 days.
The medication will normally be stopped, at least temporarily, in people who experience serious or intolerable skin reactions. If the skin reaction improves within one month, panitumumab may be restarted at a lower dose -- usually 3 mg per kg body weight (about 1.4 mg per lb). This amount may be increased slowly to the standard dosage of 6 mg per kg if skin reactions do not recur.

General Information on Receiving Panitumumab

Some considerations to keep in mind during treatment with panitumumab include the following:
  • This medication comes as a liquid (solution) that is given as a slow injection into a vein (an intravenous, or IV, infusion) every 14 days.
  • It normally takes 60 to 90 minutes to receive each dose of panitumumab. Your healthcare provider may need to slow down or temporarily stop your dose if you experience a reaction during the infusion (an infusion reaction).
  • The infusion will be given by a trained healthcare provider in a healthcare setting, such as a hospital or clinic.
  • For this drug to work properly, it must be used as prescribed. The medication will not work as well if you miss doses.
  • If you are unsure about anything related to your dosage or panitumumab dosing in general, please talk to your healthcare provider or pharmacist.
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.